Compare MFIN & CNTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MFIN | CNTN |
|---|---|---|
| Founded | 1995 | 2017 |
| Country | United States | United States |
| Employees | 179 | 12 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 229.0M | 185.3M |
| IPO Year | N/A | 2022 |
| Metric | MFIN | CNTN |
|---|---|---|
| Price | $10.94 | $1.86 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | 40.4K | ★ 757.7K |
| Earning Date | 04-29-2026 | 05-13-2026 |
| Dividend Yield | ★ 5.18% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.02 | N/A |
| P/E Ratio | $6.21 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.85 | $1.75 |
| 52 Week High | $11.05 | $5.27 |
| Indicator | MFIN | CNTN |
|---|---|---|
| Relative Strength Index (RSI) | 67.98 | 35.03 |
| Support Level | $9.20 | N/A |
| Resistance Level | N/A | $3.80 |
| Average True Range (ATR) | 0.32 | 0.17 |
| MACD | 0.11 | 0.01 |
| Stochastic Oscillator | 87.19 | 18.97 |
Medallion Financial Corp is a finance company that originates and services loans in various industries. The four operating segments are, (1) recreation, (2) home improvement, (3) commercial and (4) taxi medallion The company generates maximum revenue from the Recreation segment. The company's geographic Concentrations are in united states diversified in California, Wisconsin, New York, Texas and others.
Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company also operates a validator node on the Canton Network to facilitate transaction validation and network operations. It also operates a clinical-stage biotech research and development arm. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.